A MESSAGE FOR PATIENTS, DOCTORS, INSURERS AND EMPLOYERS WHO COUNT ON REMICADE® (infliximab)

“Patients with serious chronic diseases often go through a long and arduous journey to find a medicine that works for them and keeps their symptoms under control. We will continue to compete to make sure patients can benefit from the proven efficacy, safety and quality of REMICADE® (infliximab).” – Scott White, President, Janssen Biotech, Inc.

You may have read that Pfizer recently filed a lawsuit against us related to REMICADE® (infliximab) contracting. We want you to know some important information that Pfizer isn’t telling you:

- We are committed to ensuring patients who are successfully treated with REMICADE® continue to be able to get it and new patients have the opportunity to benefit from REMICADE®. We are competing vigorously on value and price to do that.

- Competition is doing what competition is meant to do: driving deeper discounts that will lead to overall lower costs for infliximab, including REMICADE®. We stand by our contracts.

- Since we are competing vigorously, healthcare system costs will go down while providers can keep patients on the REMICADE® they trust, with its long-established efficacy, safety and quality.

- Rather than demonstrating value and working to win the trust of physicians and patients, Pfizer is asking the court to protect it from having to compete.

- Biosimilars are not generics. The Celltrion infliximab biosimilar marketed by Pfizer in the U.S. is similar to but not the same as REMICADE®. Like any new medicine in a highly competitive class, Pfizer needs to demonstrate sufficient value to patients, providers, payers and employers to gain market share.

- Protecting Pfizer from having to compete vigorously is bad for patients, healthcare providers, payers, employers and the healthcare system.